原发性胆汁性胆管炎治疗不完全应答患者的定义与管理
本文综述原发性胆汁性胆管炎(PBC)患者接受熊去氧胆酸(UDCA)初始治疗后不完全应答的定义与管理。通常在UDCA治疗12个月后评估生化应答标志物,重症或症状明显者可在6个月评估;碱性磷酸酶超过正常上限1.5倍或胆红素升高者应考虑二线治疗,完全应答者可继续UDCA单药治疗,不完全应答者应考虑在继续UDCA基础上加用奥贝胆酸(已获批)或贝特类(未获批)。
要点
- 所有PBC患者均应接受UDCA初始治疗,应答概率基于基线特征。
- 通常在UDCA治疗12个月后评估生化应答,重症或症状明显者可在6个月评估。
- 碱性磷酸酶超过正常上限1.5倍或总胆红素及结合胆红素升高者应考虑二线治疗。
核心结论
- 应明确界定治疗应答不佳风险患者、不完全应答的生化标志物及标准化管理。
- 生化应答充分者可继续UDCA单药治疗;不完全应答者应考虑在继续UDCA基础上加用奥贝胆酸(已获批)或贝特类(未获批)。
- PBC患者应终身随访。
研究设计与样本
- 本文为综述,检索范围未在原文中报告。
主要发现
- PBC是免疫介导的慢性肝病,特征为胆管上皮损伤、胆汁淤积和进行性纤维化,可导致肝硬化和需肝移植。
- 应答标志物包括血清碱性磷酸酶和胆红素水平降低(Paris-2、Toronto、GLOBE等标准)。
- 总胆红素及结合胆红素水平高或碱性磷酸酶超过正常上限1.5倍的患者应考虑二线治疗。
关键数值与推荐
- 所有PBC患者均应接受UDCA初始治疗,应答概率基于基线特征。
- 通常在UDCA治疗12个月后评估生化应答标志物;重症或症状明显(如瘙痒或疲劳)者可在6个月评估。
- 碱性磷酸酶超过正常上限1.5倍或总胆红素及结合胆红素水平高者应考虑二线治疗。
- 生化应答充分者可继续UDCA单药治疗。
- 不完全应答者应考虑在继续UDCA基础上加用奥贝胆酸(已获批)或贝特类(未获批)。
临床怎么用
- 所有PBC患者初始治疗使用UDCA,并根据基线特征评估应答概率。
- 治疗12个月后评估生化应答,重症或症状明显者可在6个月评估。
- 生化应答充分者继续UDCA单药治疗;不完全应答者考虑加用奥贝胆酸(已获批)或贝特类(未获批)。
- PBC患者应终身随访。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is an immune-mediated chronic liver disease characterized by biliary epithelial injury, cholestasis, and progressive fibrosis that can lead to cirrhosis and requirement for liver transplantation. All patients with PBC should receive initial treatment with ursodeoxycholic acid (UDCA), and odds for response are based on characteristics at baseline. It is important to have clear definitions of patients at risk for a poor response to therapy, of biochemical markers of an incomplete response, and standardized management. Patients typically are assessed after 12 months of treatment with UDCA for biochemical markers of response. However, evaluation at 6 months has been proposed for patients with more severe disease or symptoms (such as pruritus or fatigue). Markers of response to therapy include reduced serum levels of alkaline phosphatase and bilirubin (Paris-2, Toronto, GLOBE, and so forth); patients with high levels of total and conjugated bilirubin or levels of alkaline phosphatase more than 1.5-fold the upper limit of normal should be considered for second-line therapy. Patients with adequate biochemical responses can continue UDCA monotherapy. Incomplete responders should be considered for second-line therapies with obeticholic acid (licensed) or fibrates (unlicensed) in addition to continued treatment with UDCA. Patients with PBC should be followed up for life.
引用
- Montano-Loza AJ, Corpechot C. Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. Clin Gastroenterol Hepatol. 2020. PMID: 32629125. doi:10.1016/j.cgh.2020.06.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。